Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,583 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A

NCT00858897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cysteine isotope infusion at normoglycemia vs hyperglycemia, Regular Insulin
Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 30, 2026, 1:38 AM EDT
Not yet recruiting Not applicable Interventional

Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D

NCT07501338
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem Automated Insulin Delivery System
Device
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 26 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 30, 2026, 1:38 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus

NCT05985135
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Muscle Biopsy, Jell-O with Amino acids, Dextrose
Procedure · Other · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Phase 3 Interventional

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

NCT00108004
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Anaheim, California • Escondido, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Phase 2 Interventional

Prevention of Diabetes Progression Trial (PDPT)

NCT00198146
View directory record Official record
Conditions
Newly Diagnosed With Type 1 Diabetes
Interventions
Zenapax
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes

NCT03174288
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exercise, Spironolactone
Other · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Not applicable Interventional

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes

NCT03890003
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

NCT00938405
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hyperlipidemias
Interventions
Colesevelam HCl, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Not applicable Interventional Results available

Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia

NCT00974051
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Terbutaline, 20% basal insulin reduction, Control
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 30, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional Results available

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

NCT02716805
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tremelimumab, Durvalumab, Prevnar-13, Melphalan
Drug · Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 30, 2026, 1:38 AM EDT
Recruiting Phase 2 Interventional

ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes

NCT04933851
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ACT1VATE, DSME/S
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

NCT01708044
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide acetate, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Early Phase 1 Interventional

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, hyaluronidase, Lispro-PH20
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 30, 2026, 1:38 AM EDT
Recruiting Not applicable Interventional

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

NCT06880835
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control IQ + sleep or exercise activity with TI
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

NCT02531035
View directory record Official record
Conditions
Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Concord, California • Escondido, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 30, 2026, 1:38 AM EDT
Recruiting Not applicable Interventional

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

NCT07599982
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Interventions
MODI Algorithm
Device
Lead sponsor
DreaMed Diabetes
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

NCT02018627
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Xeris glucagon, Lilly glucagon
Drug
Lead sponsor
Steven J. Russell, MD, PhD
Other
Eligibility
21 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Children's Mercy Teens With Type 1 Diabetes Will Participate in an Online Peer Support Group.

NCT06412146
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Peer Support Group
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
16 Years to 19 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 30, 2026, 1:38 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Expanding Coverage of Continuous Subcutaneous Insulin Infusion in Pediatric Patients With Diabetes

NCT00829062
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous glucose glucose sensor- physician ordered
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2010 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Not applicable Interventional Results available

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT03938324
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

NCT06007508
View directory record Official record
Conditions
DKA
Interventions
Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

NCT00095082
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin detemir, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Anaheim, California • Huntington Beach, California • Inglewood, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 30, 2026, 1:38 AM EDT
Not yet recruiting Not applicable Interventional

Pilot of Food Is Medicine Interventions to Reduce Cardiovascular Disease Risk in Children With Food Insecurity and Diabetes

NCT07590817
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Food Insecurity
Interventions
Produce prescription, Medically tailored meal kits, Nutrition Coaching
Behavioral
Lead sponsor
Katelyn Fox
Other
Eligibility
5 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 30, 2026, 1:38 AM EDT
Completed Phase 4 Interventional

Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus

NCT04030091
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
3 hours humulin R 100 IU/mL PIT, 2 hours humulin R 100 IU/mL PIT
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 30, 2026, 1:38 AM EDT